Oil Prices Rise as U.S.-Iran Fighting Fuels Supply Fears 
US Treasury Plans Weekly Iran Sanctions Push 
US Stock Futures Fall as Iran Strikes, Fed Rate Fears Rise 
Gold Prices Rebound as Fed Rate Hike Bets Rise 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Oil Prices Jump as U.S.-Iran Tensions Threaten Hormuz 
India Manufacturing Growth Slows to Five-Year Low in August 
Asian Currencies Mixed as Yen Nears 160, Oil Surges 
Brazil, US Resume Tariff Talks as Trade Tensions Persist 
Canada Backs €100 Billion Global Defence Bank 
Citi Sees Signs of Shift in Global Currency Policy 
Bessent Says Yen Moves Contained as BOJ Rate Decision Looms 
Oil Prices Jump as U.S.-Iran Tensions Threaten Hormuz Supply 
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise 
Bessent Urges G20 to Rethink China Trade Ties 
Asian Stocks Slide as U.S.-Iran Fighting Lifts Oil Prices 
Ukraine Seeks Early EU Funds to Cover $27B Defence Gap 
Add as a preferred source on Google
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
